Keytruda and Lenvima combination showed a 50.6% overall response rate and 82.3% disease control rate in advanced non-clear cell kidney cancer. The median progression-free survival was 17.9 months, ...

Since there are so many options available to treat advanced renal cell carcinoma, it may be helpful to seek out additional opinions about the best possible care.

New immunotherapy drug combinations are significantly extending survival for patients with advanced kidney cancer, one of the fastest-growing cancers in the United States, according to oncologists and ...

Dr. Bill Salter, senior director of radiation oncology at the Huntsman Cancer Institute, gives a tour of the treatment room at the Sen. Orrin G. Hatch Center for Proton Therapy at the institute in ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Add Yahoo as a preferred source to see more of our stories on Google. Kidney cancer cases are projected to nearly double by 2050, but researchers say prevention and early detection can help curb the ...

Editorial: Treatments continue to improve. The challenge now facing ministers is hugely unequal outcomes ...

The American Cancer Society’s 2026 Cancer Statistics report, released Tuesday, marks a major milestone for U.S. cancer survival rates. For the first time, the annual report shows that 70% of Americans ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...